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HOMOZYGOUS MUTATION IN HSPB1 CAUSING
DISTAL VACUOLAR MYOPATHY AND MOTOR
NEUROPATHY
Case report. A 57-year-old woman, born to parents
of Gujarati Indian descent (figure, A), presented at
age 19 with pain and stiffness in her calves and a ten-
dency to trip. In her 20s, a formal neurologic exam-
ination demonstrated predominantly distal lower
limb weakness and normal upper limb muscle
strength.1 Motor and sensory nerve conduction stud-
ies were normal with the exception that no motor
response was elicited from the extensor digitorum
brevis. Fibrillations and polyphasic action potentials
were present on EMG. The creatine kinase (CK) level
was 1,452 IU/L. A quadriceps muscle biopsy was
performed at age 27 from which images were available
in the records.1 At that time, muscle fiber diameters
were large ranging from 50 to 80 mm. Many of the
fibers contained single or multiple unrimmed va-
cuoles that appeared empty in the modified Gomori
trichrome preparation (figure, B.a). There was no
increase in endomysial connective tissue or evidence
of inflammation, necrosis, or regeneration. There was
no evidence of glycogen, increased lipid, or acid phos-
phatase staining in the vacuoles (figure, B.b). The
ATPase at pH 9.5 demonstrated that most of the
vacuolated fibers were of type 2, and electron micros-
copy showed electron-dense material within vacuoles
(figure, B.c and d).1 The overall appearances were
those of a vacuolar myopathy without any features
suggesting neurogenic change, and she was diagnosed
with a distal myopathy.1
She re-presented at age 57 following the develop-
ment of slowly progressive severe upper and lower
limb weaknesses. On examination at age 57, there
was evidence of distal more than proximal upper
limb weakness affecting wrist extension (Medical
Research Council [MRC] grade 41/5), finger
extension (4 1 5), first dorsal interossei (1/5),
abductor pollicis brevis (3/5 right and 4/5 left),
and abductor digiti minimi (3/5 right and 4/5 left).
In the lower limbs, she had severe proximal weak-
ness (grade 2/3) with no movement at the ankles.
Sensory modalities were preserved except for
reduced vibration sense at the ankles. She was
areflexic. Her CK level was 404 IU/L. Neurophys-
iologic studies suggested an axonal motor neurop-
athy. Sensory nerve action potentials were,
nevertheless, at the lower limit of normal for ampli-
tude in the lower limbs (right sural 6 mV, right
superficial peroneal 7 mV, and normal range .5 mV),
and distal lower limb motor responses were absent.
Needle EMG showed prominent chronic neuro-
genic changes with large motor units recruiting in
reduced numbers but at increased firing rates to
a reduced interference pattern. This EMG pattern
was most pronounced distally but evident proxi-
mally in the upper and lower limbs. No low ampli-
tude or brief polyphasic motor units were seen on
any occasion at re-presentation. Muscle MRI was
performed, showing widespread severe muscle fatty
replacement (figure, C).
There was no relevant family history. Her mother
has diabetes and her father a right above knee ampu-
tation for peripheral vascular disease. Neither had
neurologic complaints. However, clinical examina-
tion of both in their 80s revealed mild distal weakness
(MRC grade 4/5) in the upper and lower limbs with
areflexia. Pinprick sensation was reduced to the mid-
forearm and foot in her mother. Her father had
reduced vibration sense to the left ankle. Neurophys-
iologic testing was not possible in either.
Targeted exome sequencing of the proband’s
DNA using the Agilent Focused Exome kit identified
a homozygous variant (c.418C.G, p.Arg140Gly) in
HSPB1, which was confirmed by Sanger sequencing.
Both parents were heterozygous. We have reported
this variant previously in heterozygous form in indi-
viduals from 5 Indian Gujarati families with distal
motor neuropathy.2
Discussion. Our patient presented at age 19 with
clinical and biopsy features consistent with a distal
myopathy. Prominent vacuoles in type 2 fibers con-
tained granular, electron-dense material (figure, B)
that was interpreted to represent the product of myo-
fibrillar degeneration.1 At presentation, neurophysio-
logic studies did show fibrillations and polyphasic
action potentials. However, nerve conduction studies
were normal with the exception of 1 absent motor
nerve response, and overall, the clinical image was felt
to represent a distal myopathy at this time. Subsequent
Neurology.org/ng Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology 1
neurophysiologic studies performed at age 57 follow-
ing progressive limb weakness revealed an axonal
motor neuropathy. Although chronic end-stage
myopathy may have neurophysiologic features that
can appear neurogenic, in this case, even the less
affected proximal limb muscles failed to demonstrate
any myopathic motor units or myopathic recruitment.
HSPB1 is a small heat-shock protein highly ex-
pressed in striated muscle with an important role in
maintaining myofibrillar structure during stress
conditions.3
Mutations in HSPB1, HSPB3, and HSPB8 are
classically associated with motor neuropathy.4 HSPB5
(CRYAB) has been associated with a wide spectrum of
clinical manifestations including desmin-related myo-
fibrillar myopathy. The protein position of the
Arg140Gly HSPB1 mutation in our case corresponds
to the Arg120 HSPB5 residue mutated in this myop-
athy (figure, D).4 Heterozygous mutations in HSPB8
have recently been reported causing neuropathy and
distal myopathy with rimmed vacuoles and fibrillar
aggregates in 2 families.5 Subsequently, distal
myopathy and neuronopathy have been attributed
to an HSPB1 mutation in 1 family.6 We describe
a patient with a homozygous HSPB1 mutation also
presenting with a distal vacuolar myopathy, motor
neuropathy, and minimal sensory involvement, sup-
porting the association of HSPB1mutations with this
phenotype. This expands the genetic testing indicated
in distal vacuolar myopathy.
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Figure Clinical-pathologic features of patient homozygous for the HSPB1 p.Arg140Gly mutation and protein conservation between species
(A) Family pedigree: an arrow indicates the proband; half-filled indicates distal weakness in parents who were heterozygous for p.Arg140Gly mutation. (B)
Biopsy of the quadriceps muscle performed at age 27; (B.a) modified Gomori trichrome staining shows variation in fiber diameter and prominent vacuoles
within many muscle fibers, arrows; (B.b) Periodic acid–Schiff preparation showed no evidence of glycogen accumulation within vacuoles (arrows); (B.c)
ATPase pH 9.5 demonstrates that vacuoles are predominantly in darkly stained type 2 fibers, arrows; and (B.d) ultrastructural examination of the muscle
revealed electron-dense material within vacuoles (arrows). (C) Muscle MRI demonstrating severe widespread fatty infiltration of pelvic, thigh, and calf
muscles with relative sparing of the adductor longus (red arrows). (D) Conservation of HSPB1 and HSPB5 (CRYAB) amino acid sequence between species.
The Arg140 residue in HSPB1 is well conserved and corresponds to the position of Arg120 in the CRYAB gene.
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